Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique

• US 7,963,956 B2
• Filed: 04/22/2003
• Issued: 06/21/2011
• Est. Priority Date: 04/22/2003
• Status: Expired due to Fees

• Current Assignee: Antisense Pharma GmbH
• Original Assignee: Antisense Pharma GmbH
• Inventors: Kunst, Mechthild
• Primary Examiner(s): DeSanto; Matthew F
• Application Number:
  US10/420,094
• Publication Number:
  US 20040215173A1
• Time in Patent Office: 2,982 Days
• Field of Search: 604/20, 604 65- 67, 604131-135, 604/153, 60428801-28804, 604/890.1, 604/891.1, 604/892.1, 604/93.01, 604/500, 604/504, 604/522, 128/DIG.13, 128/DIG.12
• US Class Current: 604/890.1
• CPC Class Codes: A61M 2005/1581 Right-angle needle-type devices
• CPC Class Codes: A61M 2039/0211 with multiple chambers in a single site
• CPC Class Codes: A61M 2205/32 with radio-opaque indicia
• CPC Class Codes: A61M 2210/0693 Brain, cerebrum
• CPC Class Codes: A61M 39/0208 Subcutaneous access sites for injecting or removing fluids transcutaneous access sites A61M39/0247; implantable infusion devices A61M5/14276
• CPC Class Codes: A61M 39/04 having pierceable self-sealing members
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body

Abstract

The present invention is directed to a device for a portable convection enhanced delivery system that allows administering liquids to specific locations within the body, especially tissues and tumors also allowing outsubject treatment. The application system comprises a portable extracorporal pump with a fluid reservoir that is connected via an infusion system to an infusion catheter placeable to any tissue or tumor the fluid should be administered to by high flow microperfusion. The system enables administration of fluids of any kind by convection enhanced delivery also in out-patient treatment. The system can be used for delivering various drugs, proteins, protein toxins, antibodies-for treatment or imaging, proteins in enzyme replacement therapy, growth factors and viruses or oligonucleotides in gene therapy etc. The application methods as well as the surgical method to implant this device are enclosed to this invention.

Claims

1. An apparatus comprising:

a. an extracorporeal solvent reservoir comprising a distal portion, a proximal port and a lumen extending therethrough;

b. an extracorporeal portable pump comprising a proximal port and a distal port and a lumen therethrough wherein the extracorporeal portable pump is in fluid communication with the extracorporeal solvent reservoir;

c. an infusion catheter configured for insertion into the tumor of the subject, the infusion catheter comprising a length extending from a proximal end for introduction into the tumor to a distal end with a lumen extending between the proximal end and the distal end wherein the infusion catheter is in fluid communication with the solvent reservoir and portable pump; and

d. an intracorporeal access port comprising an access port chamber having a proximal port, a distal port and a lumen extending therebetween, wherein the intracorporeal access port is located proximal from the extracorporeal portable pump and facilitate fluid communication between

(i) the extracorporeal solvent reservoir and extracorporeal portable pump and

(ii) the infusion catheter; and

(e) means for convection enhanced delivery of a solvent to a target tumor, wherein the solvent delivered by convection enhanced delivery has (i) a flow rate at the target tumor of more than 0.001 ml/h and less than 1 ml/h;

(ii) a total flow volume within one period of any oscillation of less than about 0.5 μ

l; and

(iii) an amplitude of oscillation between about 0.05 ml/h and about 1 ml/h.

2. The apparatus of claim 1, further comprising:

a. an access port catheters comprising a proximal port, a distal port, and a lumen extending therethrough, wherein the proximal port of the access port catheter is in fluid communication with (i) the infusion catheter lumen and (ii) the distal port of the access port chamber;

b. an infusion tubes configured for connection to the distal port of the access port chamber, the infusion tube comprising a length extending from a proximal end for introduction into the distal end of the access port chamber to a distal port opposite the proximal end, and a lumen extending therethrough.

3. The apparatus of claim 2, wherein the access port chamber is configured to be penetrated by a needle once or a multiple of times without loosing fluid containment integrity.

4. The apparatus of claim 3, wherein the infusion tube further comprises an access port-needle at the proximal port of the infusion tube adopted for insertion into the distal port of the access port chamber.

5. The apparatus of claim 4, wherein the access port-needle is configured to be replaced or exchangeable.

6. The apparatus of claim 4, wherein the access port-needle comprises an angle between 90°

to about 180°

.

7. The apparatus of claim 4, wherein the access port-needle is protected by a cap lined with a ring of a soft material.

8. The apparatus of claim 3, wherein the access port comprises a housing with a chamber of an inert material and covered by a pliable septum at the distal end.

9. The apparatus of claim 2, further comprising a one-way valve, each valve configured so as to not allow fluid to flow from the infusion catheter to the solvent reservoir.

10. The apparatus of claim 9, wherein the one-way valve is disposed adjacent to the solvent reservoir.

11. The apparatus of claim 2, further comprising a filter system.

12. The apparatus of claim 11, wherein the filter system comprises a filter having a pore size of about 0.22 μ

m or less.

21. The apparatus of claim 1, wherein the solvent reservoir comprises an elastically compressible solvent reservoir.

22. The apparatus of claim 21, wherein the reservoir comprises a polymeric material.

23. The apparatus of claim 1, wherein the portable pump comprises a gas pressure pump, a membrane pump, a piston pump, a radial piston pump, a syringe pump, a centrifugal pump, or a suction pump.

24. The apparatus of claim 1, comprising two or more infusion cathers,and further comprising a disributor.

13. The apparatus of claim l, wherein at least one of (i) a lumen which contacts the solvent, (ii) an infusion catheter or (iii) an intracorporeal access port is sterile.

14. The apparatus of claim 13, wherein at least one of the surfaces in contact with the solvent or the surface of an infusion catheter or an access port are coated.

15. The apparatus of claim 14, wherein the access port chamber and the access port catheter are implanted in the subject and the infusion catheter is implanted into the target tumor and in fluid communication with the access port.

16. The apparatus of claim 15, wherein the solvent comprises a fluid pharmaceutical agent.

17. The apparatus of claim 16 wherein the fluid pharmaceutical agent is selected from the group consisting of:

an analgetic, an agent for the treatment of a wound, an analeptic, an anesthetic, an anthelmintic, an anticoagulant, an antirheumatic, an antiallergic, an antiarrhythmic, an antibiotic, an antidementive, an antidiabetic, an antidote, an antiepileptic, an antihemorrhaqic, an antihypertonic, an antihypnotic, an anti migraine agent, an antimycotic, an antineoplastic agent, an anti-Parkinson agent, an antiphlogistic, an antisense oligonucleotide, an antituberculosis agent, an anti-arteriosclerotic agent, a biologic material, a blood flow stimulant, a cholagogas, a corticoid, a cytokine, a cytostatic, a diagnostic agent, a fibrinolytic, a geriatric agent, a gonadotropin, a hepatic, a hormone and/or their inhibitors, a hypnotic, an immunoglobulin, an immunomodulator, an immunotherapeutic agent, an organ perfusion solvent, a protein, a protein toxin, a protective, a sedative, a cardiac agent, a depressant, a stimulant, a mineral, a muscle relaxant, a neurotropic agent, an oligonucleotide, an ophthalmic, an osteoporosis agent, an otologic, a psychotropic agent, a sera, a thyroid preparation, a vaccine, a spasmolytic, an urologic agent, a vitamin, an antibody, a protein in enzyme replacement therapy, a growth factor, a vector, a virus in gene therapy, an agent for diagnosis, an agent or antibody for imaging, or a x-ray contrasting medium, and combinations thereof.

18. The apparatus of claim 16, wherein the fluid pharmaceutical agent comprises an antisense oligonucleotide that inhibits the expression of TGF-β

, MIA, c-erbB-2/HER-2, or IL-10, and combinations thereof.

19. The apparatus of claim 15, wherein the tumor comprises blastoma, breast cancer, esophageal cancer, head and neck cancer, ovarian cancer, sarcoma (including osteosarcoma and chondrosarcoma), small-cell bronchogenic/lung carcinoma, non-small-cell bronchogenic/lung carcinoma, colon carcinoma, colorectal carcinoma, gastric cancer, small intestine carcinoma, liver carcinoma, carcinoma of the kidney, pancreas carcinoma, gallbladder cancer, cervical carcinoma, endometrial cancer, mesothelioma, prostate carcinoma, testicular carcinoma, brain tumor, non-Hodgkins lymphoma, Hodgkins-lymphoma, or neoplasma.

20. The apparatus of claim 19, wherein the neoplasm is a glioma.

25. A method of using an apparatus to administer a solvent to a tumor in a subject, the apparatus comprises:

(i) an extracorporeal solvent reservoir comprising a distal portion, a proximal port and a lumen extending therethrough;

(ii) an extracorporeal portable pump comprising a proximal port and a distal port and a lumen therethrough wherein the extracorporeal portable pump is in fluid communication with the extracorporeal solvent reservoir;

(iii) an infusion catheter configured for insertion into the tumor of the subject, the infusion catheter comprising a length extending from a proximal end for introduction into the tumor to a distal end with a lumen extending between the proximal end and the distal end wherein the infusion catheter is in fluid communication with the solvent reservoir and portable pump;

(iv) an intracorporeal access port comprising an access port chamber having a proximal port, a distal port and a lumen extending therebetween, wherein the intracorporeal access ports are located proximal from the extracorporeal portable pump and facilitate fluid communication between (x) the extracorporeal solvent reservoir and extracorporeal portable pump and (v) the infusion catheter;

(v) an access port catheter comprising a proximal port, a distal port, and a lumen extending therethrough, wherein the proximal port of the access port catheter is in fluid communication with (x) the infusion catheter lumen and (y) the distal port of the access port chamber; and

(vi) an infusion tube configured for connection to the distal port of the access port chamber, the infusion tube comprising a length extending from a proximal end for introduction into the distal end of the access port chamber to a distal port opposite the proximal end, and a lumen extending therethrough;

the method of using the apparatus comprising the steps of;

a. implanting an infusion catheter into the tumor of a subject;

b. implanting an access port catheter and access port chamber into the subject;

c. connecting the distal port of the infusion catheter to the proximal port of an access port catheter;

d. connecting the distal port of an access port catheter to the proximal port of the access port chamber;

e. connecting the distal port of the access port chamber to the proximal end of an infusion tube;

f. connecting the proximal port of the portable pump to the distal port of an infusion tube; and

g. delivering a solvent to the tumor by convection enhanced delivery having (i) a flow rate at the target tumor of more than 0.001 ml/h and less than 1 ml/h;

(ii) a total flow volume within one period of any oscillation of less than about 0.5 μ

l; and

(iii) an amplitude of oscillation between about 0.05 ml/h and about 1 ml/h.

26. The method of claim 25, wherein the solvent is exchanged with a fluid pharmaceutical agent or a physiologic solvent in interval therapy.

27. The method of claim 26, wherein the solvent is administered for about 3-7 days.

28. The method of claim 27, wherein the physiological solvent is administered for about 3-7 days.

29. The method of claim 27, wherein the interval therapy is about 2-20 cycles.

30. The method of claim 26, wherein a solvent comprises a fluid pharmaceutical solvent and is administered to the tumor by the apparatus.

31. The method of claim 25, wherein the solvent is administered to the tumor at a constant flow rate, an increasing flow rate, or a decreasing flow rate, or combinations thereof, in the infusion catheter.

32. An apparatus comprising:

(a) means for injecting a solvent into a tumor or tissue of a subject in fluid communication with an accessory system;

(b) an access port having a proximal port, a distal port, and a lumen extending therethrough;

(c) an access port catheter having a proximal port, a distal port, and a lumen extending therethrough, the proximal port of the access port catheter is in fluid communication with the distal port of the infusion catheter and the distal port of the access port catheter is in fluid communication with the access port;

(d) an infusion catheter configured for insertion into the tissue or tumor of the subject, the infusion catheter having a length extending from a proximal end for introduction into the tissue to a distal end opposite the proximal end, and a lumen extending therethrough; and

(e) means for convection enhanced delivery of a solvent to a target tumor, wherein the solvent delivered by convection enhanced delivery has (i) a flow rate at the target tumor of more than 0.001 ml/h and less than 1 ml/h;

(ii) a total flow volume within one period of any oscillation of less than about 0.5 μ

l; and

(iii) an amplitude of oscillation between about 0.05 ml/h and about 1 ml/h.

33. The apparatus of claim 32, wherein the accessory system comprises an access port-needle located at the proximal port of the means for injecting and adapted for insertion into the distal port of the access port chamber.

34. The apparatus of claim 33 further comprising a one-way valve configured to prevent fluid flow from the infusion catheter to the solvent reservoir.

35. The apparatus of claim 34 with the one-way valve disposed adjacent to the means for injecting a solvent.

36. The apparatus of claim 33, wherein the access port-needle is configured to be replaceable or exchangeable.

37. The apparatus of claim 33, wherein the access port-needle comprises an angle between about 90°

to about 180°

.

38. The apparatts of claim 33, wherein the access port-needle is protected with a cap, lined with a ring of a soft material.

39. The apparatus of claim 32, comprising two or more infusion catheters and a distributor.

40. The apparatus of claim 39, wherein the access port chamber is configured to be penetrated by a needle once or a multiple of times.

41. The apparatus of claim 40, wherein the access port comprises a housing with a chamber of an inert material covered by a pliable septum at the distal end.

42. The apparatus of claim 32, wherein the solvent comprises a fluid pharmaceutical agent.

43. The apparatus of claim 42, wherein the fluid pharmaceutical agent is selected from solvents or suspensions of agents selected from the group consisting of:

analgetics, agents for the tratement of wounds, analeptics, anesthetics, anthelmintics, anticoagulatives, antirheumatics, antiallergics, antiarrhythmics, antibiotics, antidementiva, antidiabetica, antidotes, antiepileptics, antihamorrhagics, antihypertonics, antihypnotics, anti migrain preparation, antimycotics, antineoplasics, antiparkinson agents, antiphlogistics, antisense oligonucleotides, antituberculosis drugs, arterisclerotic agents, biologic materials, blood flow stimulants, cholagogas, corticoids, cytokines, cytostatics, diagnostics, fibrinolytics, geriatrics, gonadotropins, hepatics, hormones and their inhibitors, hypnotics, immunglobulines, immunmodulators, immunotherapeutics, organ perfusion solvents, proteins, protein toxins, protectives, sedatives, cardiac remedies, depressants and stimulants, minerals, muscle relaxants, neurotropic agents, oligonucleotides, ophthalmics, osteoporotic agents, otologics, psychopharmaceuticals, sera, thyroid preparations, vaccines, spasmolytics, urologics, vitamins, drugs, proteins, protein toxins, antibodies for treatment, proteins in enzyme replacement therapy, growth factors, vectors, viruses in gene therapy, agents for diagnosis as agents, antibodies for imaging, or x-ray contrasting agents, and combinations thereof.

44. The apparatus of claim 42, wherein the fluid pharmaceutical agent comprises antisense oligonucleotides inhibiting the expression of TGF-β

, MIA, c-erbB-2/HER-2, or IL-10, and/or combinations thereof.

45. The apparatus of claim 32, further comprising a filter system.

46. The apparatus of claim 45, wherein the filter system comprises a filter having a pore size of about 0.22 μ

m or less.

47. The apparatus of claim 32, wherein the tumor comprises blastoma, breast cancer, esophageal cancer, head and neck cancer, ovarian cancer, sarcoma (including osteosarcoma and chondrosarcoma), small-cell bronchogenic/lung carcinoma, non-small-cell bronchogenic/lung carcinoma, colon carcinoma, colorectal carcinoma, gastric cancer, small intestine carcinoma, liver carcinoma, carcinoma of the kidney, pancreas carcinoma, gallbladder cancer, cervical carcinoma, endometrial cancer, mesothelioma, prostate carcinoma, testicular carcinoma, brain tumor, non-Hodgkins lymphoma, Hodgkins-lymphoma, or neoplasm.

48. The apparatus of claim 47, wherein the neoplasm is a glioma.

49. The apparatus of claim 32, wherein at least one of the lumens that contact the solvent, an access port or an access port catheter is sterile.

50. The apparatus of claim 32, wherein at least one or more surfaces that come in contact with the solvent or an intracorporeal component are coated.

51. The apparatus of claim 32, wherein the access port chamber and the access port catheter are implanted in the subject and the infusion catheter is implanted into the target tumor or tissue and in fluid communication with the access port catheter.

52. The apparatus of claim 32, wherein the tissue comprises brain, bone marrow, bone, joints, thyroid, gall, heart, lung, muscle, spleen, kidney, liver, prostate, pancreas, stomach, vein, or artery.

53. A method of using an apparatus to administer a solvent to a tissue or a tumor of a subject, the apparatus comprising:

(i) means for injecting a solvent into a tumor or tissue of a subject in fluid communication with an accessory system;

(ii) an access port having a proximal port, a distal port, and a lumen extending therethrough;

(iii) an access port catheter having a proximal port, a distal port, and a lumen extending therethrough, the proximal port of the access port catheter is in fluid communication with the distal port of the infusion catheter and the distal port of the access port catheter is in fluid communication with the access port; and

(iv) an infusion catheter configured for insertion into the tissue or tumor of the subject, the infusion catheter having a length extending from a proximal end for introduction into the tissue to a distal end opposite the proximal end, and a lumen extending therethrough;

the method of using the apparatus comprising the steps of;

(a) implanting an infusion catheter into the tissue or the tumor of a subject;

(b) implanting the access port catheter and access port chamber into the subject;

(c) connecting the distal port of the infusion catheter to the proximal port of the access port catheter;

(d) connecting the distal port of the access port catheter to the proximal port of the access port chamber;

(e) connecting the distal port of the access port chamber to the proximal end of infusion tube;

(f) connecting the means for injecting a solvent to the distal port of the infusion tube; and

(g) delivering a solvent to the tissue or tumor of the subject by convection enhanced delivery having (i) a flow rate at the target tumor of more than 0.001 ml/h and less than 1 ml/h;

(ii) a total flow volume within one period of any oscillation of less than about 0.5 μ

l; and

(iii) an amplitude of oscillation between about 0.05 ml/h and about 1 ml/h.

54. The method of claim 53, wherein the fluid pharmaceutical solvent is exchanged with another fluid pharmaceutical agent and/or a physiological solvent in interval therapy.

55. The method of claim 54, wherein the fluid pharmaceutical solvent is administered for about 3-7 days.

56. The method of claim 54, wherein the physiological solvent is administered for about 3-7 days.

57. The method of claim 54, wherein the interval therapy is about 2-20 cycles.

58. The method of claim 53, wherein the administration of the solvent to the tissue or tumor of a subject is by a constant, increasing and/or decreasing flow.

59. A method of using an apparatus to administer a solvent to a tumor in a subject, the apparatus comprises:

(i) an extracorporeal solvent reservoir comprising a distal portion, a proximal port and a lumen extending therethrough;

(ii) an extracorporeal portable pump comprising a proximal port and a distal port and a lumen therethrough wherein the extracorporeal portable pump is in fluid communication with the extracorporeal solvent reservoir;

(iii) an infusion catheter configured for insertion into the tumor of the subject, the infusion catheter comprising a length extending from a proximal end for introduction into the tumor to a distal end with a lumen extending between the proximal end and the distal end wherein the infusion catheter is in fluid communication with the solvent reservoir and portable pump; and

(iv) an intracorporeal access port comprising an access port chamber having a proximal port, a distal port and a lumen extending therebetween, wherein the intracorporeal access port is located proximal from the extracorporeal portable pump and facilitate fluid communication between (x) the extracorporeal solvent reservoir and extracorporeal portable pump and (y) the infusion catheter;

the method of using the apparatus comprising the steps of;

a. implanting an infusion catheter into the subject;

b. implanting access port chamber into the subject;

c. connecting the proximal port of the access port chamber to the distal port of infusion catheter such that the proximal port of the access port chamber and the distal port of infusion catheter are in fluid communication;

d. connecting the distal port of the portable pump to the proximal port of the solvent reservoir;

e. connecting the proximal port of the pump to the distal port of the access port chamber to facilitate fluid communication between the solvent reservoir and the infusion catheter; and

f. delivering a solvent to the tumor by convection enhanced delivery having (i) a flow rate at the target tumor of more than 0.001 ml/h and less than 1 ml/h;

(ii) a total flow volume within one period of any oscillation of less than about 0.5 μ

l; and

(iii) an amplitude of oscillation between about 0.05 ml/h and about 1 ml/h.